Molina Healthcare Skyrizi Prior Authorization Automation

Navigating Molina Healthcare Skyrizi prior authorization for risankizumab can be complex due to state-specific requirements and diverse plan types. Klivira streamlines this process, ensuring accurate and timely submissions.

Revenue cycle teams and prior authorization coordinators face significant administrative burden managing specialty drug approvals, particularly for high-cost biologics like Skyrizi. With Molina Healthcare's varied lines of business—including Medicaid managed care, D-SNP, and ACA Marketplace plans—understanding the correct submission channel and policy application is critical to reducing denials and accelerating patient access.

Understanding Skyrizi (Risankizumab) for Molina Healthcare Patients

Skyrizi, an IL-23 inhibitor (risankizumab) manufactured by AbbVie, is indicated for conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. As a specialty biologic, Skyrizi typically requires prior authorization from Molina Healthcare to ensure medical necessity and adherence to utilization management criteria.

Molina Healthcare Prior Authorization Channels for Skyrizi

Molina Healthcare's prior authorization process for Skyrizi varies significantly based on the member's plan type and state. Medical benefit submissions, common for infused or provider-administered doses, are routed through state-specific provider portals, often accessed via Availity or directly through Molina's state-specific sites.

Submitting Medical Benefit PAs to Molina

State-Specific Portals: Molina operates distinct medical benefit PA processes for each state Medicaid managed-care contract, such as in California, Texas, Florida, and Ohio.
Availity Integration: While Availity serves as a common portal for many payers, specific Molina state plans may direct providers to proprietary state-run or Molina-specific portals for medical benefit PA submissions.
X12 278 Transactions: Klivira supports electronic submission of X12 278 transactions for medical PAs where available, automating data exchange directly with Molina or its clearinghouse partners.

Pharmacy Benefit PAs for Skyrizi with Molina

For Skyrizi dispensed under the pharmacy benefit, prior authorization workflows typically leverage ePA platforms. Klivira integrates with common pharmacy ePA partners like CoverMyMeds and Surescripts to facilitate efficient submission, though Molina's PBM relationships are state-specific and require verification.

Navigating Molina's Diverse Plan Types for Skyrizi PA

Molina Healthcare serves members across multiple plan types, each with unique prior authorization considerations. Dual-eligible Special Needs Plans (D-SNP) combine Medicare Advantage organization determination rules with state Medicaid guidelines, while ACA Marketplace plans follow Qualified Health Plan (QHP) regulations and state insurance mandates.

Klivira's Approach to Molina Healthcare Skyrizi PA Automation

Klivira's platform provides state-aware routing and intelligent form completion for Molina Healthcare Skyrizi prior authorizations. By integrating with EMRs and leveraging a dynamic policy library, we ensure submissions align with the correct state Medicaid rules, D-SNP requirements, or QHP guidelines, improving first-pass approval rates.

Accessing Molina's Utilization Management Policies

Molina Healthcare publishes its utilization management criteria, including those for specialty drugs like Skyrizi, through state-specific provider websites. Klivira's system helps identify and apply the relevant state-specific policy during the prior authorization process, ensuring submissions meet current clinical requirements.

Frequently asked questions

How do I submit a prior authorization for Skyrizi to Molina Healthcare?

Submissions for Skyrizi to Molina Healthcare depend on the benefit (medical or pharmacy) and the member's state and plan type. Medical PAs are typically submitted via state-specific provider portals or Availity, while pharmacy PAs often use ePA platforms like CoverMyMeds or Surescripts. Klivira automates routing to the correct channel.

What are the typical turnaround times for Skyrizi prior authorizations with Molina?

Prior authorization turnaround times for Molina Healthcare are primarily governed by state Medicaid mandates for managed-care plans and CMS-0057-F for all applicable lines of business, including Medicaid managed-care, D-SNP MA, CHIP, and QHP-on-FFM. Klivira's system applies the correct decision timeframe expectations.

Where can I find Molina Healthcare's utilization management policies for Skyrizi?

Molina Healthcare publishes its utilization management criteria, including drug-specific policies for Skyrizi (risankizumab), on its state-specific provider websites. These sites are typically accessible through the main molinahealthcare.com providers landing page.

Does Klivira integrate with Molina Healthcare for Skyrizi prior authorizations?

Yes, Klivira integrates with Molina Healthcare to automate prior authorizations for drugs like Skyrizi. Our platform handles the complexities of Molina's state-specific routing and diverse plan types (Medicaid, D-SNP, Marketplace), ensuring submissions comply with relevant state and federal regulations.

Are there specific considerations for Skyrizi PA for Molina D-SNP or Marketplace members?

Yes, D-SNP members require PA workflows that integrate both Medicare Advantage organization determination rules and state Medicaid coverage rules. For Marketplace plans, prior authorizations adhere to Qualified Health Plan (QHP) requirements and state insurance regulations. Klivira accounts for these layered rules.